Novartis

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ: ONXX)...

AstraZeneca (NYSE: AZN) announced Monday that it will purchase privately held Pearl Therapeutics for up to $1.15 billion in its continuing drive to reinvigorate its product pipeline. The acquisition of the U.S. based respiratory drug specialist Pearl gives AstraZeneca a foothold in the newest...

It is not unusual for stocks on a tear to overrun their mean price targets, which is a signal of how far analysts on average expect the share price to climb. Some of the top-performing health care stocks over the past six months that pay dividends, such as Becton, Dickinson (NYSE: BDX), Bristol-...

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates. The number of shares sold short in Alexion Pharmaceuticals (...

Dow Jones Industrial Average companies Chevron (NYSE: CVX), Exxon Mobil (NYSE: XOM), IBM (NYSE: IBM) and Johnson & Johnson (NYSE: JNJ) are about due to boost their payouts, according to a report on CNBC. These blue chips have significant cash hoards, buy back shares and are doing well now, as...

Some smaller health care companies saw unusual movement in their stocks on Friday. And not just in Anacor Pharmaceuticals (NASDAQ: ANAC), Halozyme Therapeutics (NASDAQ: HALO), Puma Biotechnology (NYSE: PBYI) and Questcor Pharmaceuticals (NASDAQ: QCOR), which are discussed below. But also ACADIA...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...

Bank of America Merrill Lynch offered some defensive stock picks for 2013 in a research report. Two drug makers and an REIT focused on health care facilities made the list. They were Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE) and Ventas (NYSE: VTR). Here is a quick look at how these three picks...

This weekend in Barron's online: stock picks for 2013, speculation about who will be the next Treasury chief and the prospects for Men's Wearhouse, Crosstex Energy and big pharma. Cover Story "Our 10 Favorite Stocks for 2013" by Andrew Bary. Barron's takes a look at where to invest in 2013. The...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...

Here is a quick look at three top-performing biotech stocks, each with a consensus recommendation (among analysts) of Strong Buy. They are Ariad Pharmaceuticals (NASDAQ: ARIA), Merrimack Pharmaceuticals (NASDAQ: MACK) and Synageva BioPharma (NASDAQ: GEVA). Ariad Pharmaceuticals Shares of this...